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The contribution of Epstein–Barr virus (EBV) strain variation to the pathogenesis of virus-associated tumours remains
unknown. Given the central role of LMP1 in EBV-induced transformation, much interest has focused on the influence of LMP1
sequence variation on the signaling pathways and multiple downstream phenotypic consequences of LMP1 expression. The
identification of LMP1 variants with a common 10-amino-acid deletion and additional point mutations (typified by the
CAO-LMP1 isolate) in EBV strains associated with nasopharyngeal carcinoma prompted us to examine the effect of stable
prototype B95.8-LMP1 and CAO-LMP1 expression on the phenotype and differentiation of SCC12F human epithelial cells.
Both forms of LMP1 were able to induce expression of the antiapoptotic A20 protein and provide protection from tumour
necrosis factor-a-induced cytotoxicity. Although B95.8-LMP1 induced growth inhibition, expression of certain cell surface
molecules (CD40, CD44, and CD54), and secretion of interleukin-6 and -8 in SCC12F cells, stable CAO-LMP1 expression failed
to elicit these effects. Furthermore, B95.8-LMP1, but not CAO-LMP1, induced alterations in cell morphology and blocked
epithelial cell differentiation. Both B95.8-LMP1 and CAO-LMP1 induced similar levels of nuclear factor-kB activation, but the
ability of CAO-LMP1 to activate the AP-1 pathway was relatively impaired. These data highlight significant functional
differences between the prototype B95.8-LMP1 and the CAO-LMP1 variant when stably expressed in human epithelial cells
and suggest that continued analysis of LMP1 variants will help to further dissect the signaling pathways activated by LMP1
as well as provide insights into the contribution of LMP1 sequence variation to the pathogenesis of EBV-associated tumours.
© 2000 Academic Press
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Epstein–Barr virus (EBV), a ubiquitous human herpes-
virus, is associated with the development of tumours of B
cell origin (Burkitt’s lymphoma, immunoblastic lym-
phoma, Hodgkin’s disease) and of epithelial cell origin
[nasopharyngeal carcinoma (NPC), gastric adenocarci-
nomas] (Osato and Imai, 1996; Raab-Traub, 1996; Rickin-
son and Kieff, 1996). An in vitro corollary of the oncogenic
capacity of EBV is its ability to transform resting B cells
into permanently growing lymphoblastoid cell lines in
which every cell carries multiple episomal copies of the
virus genome and expresses a limited set of virus-en-
coded nuclear (EBNA) and membrane (LMP) proteins
(Kieff, 1996). Of these viral proteins, the latent membrane
protein 1 (LMP1) is particularly interesting because it
displays classic oncogene activity in rodent fibroblast
transformation assays and is capable of inducing a wide
range of phenotypic effects in both B cells and epithelial
cells (Kieff, 1996). Recent work demonstrates that LMP1
is essential for EBV-induced B cell transformation (Kaye
et al., 1993; Izumi and Kieff, 1997a) consistent with itsi
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204expression in various EBV-associated tumours such as
Hodgkin’s disease and NPC (Rickinson and Kieff, 1996).
In both B cells and epithelial cells, LMP1 has been
shown to induce the expression of certain cell surface
molecules (CD40, CD54) (Wang et al., 1988,1990) and of
cell survival genes such as A20, Bcl-2, and Mcl-1 (Hen-
derson et al., 1991; Laherty et al., 1992; Rowe et al., 1994;
Wang et al., 1996; Miller et al., 1997). Additional effects in
epithelial cells include up-regulation of interleukin (IL)-6
and IL-8 secretion (Eliopoulos et al., 1997; Eliopoulos et
al., 1999) and induction of the EGF receptor (EGFR)
(Miller et al., 1995, 1997, 1998a). Of particular relevance
to NPC is the ability of LMP1 to transform epithelial cells
and to block terminal differentiation (Dawson et al., 1990;
Fahraeus et al., 1990; Wilson et al., 1990; Hu et al., 1993).
Functional studies have revealed that LMP1 can activate
the nuclear factor (NF)-kB and JNK/p38 mitogen-acti-
vated protein (MAP) kinase pathways and that these are
responsible for the diverse phenotypic effects of LMP1
(Mosialos et al., 1995; Kieff, 1996; Eliopoulos et al., 1997,
998, 1999; Kieser et al., 1997; Izumi and Kieff, 1997b;
liopoulos and Young, 1998). Two major effector regions
ave been identified in LMP1 (Huen et al., 1995): a
embrane proximal CTAR1 domain (residues 194–232),
hich weakly activates NF-kB and p38 through directnteraction with members of the TRAF (TNF receptor-
ssociated factor) family, and a membrane distal CTAR2
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205FUNCTIONAL DIFFERENCES BETWEEN B95.8-LMP1 AND CAO-LMP1domain (residues 351–386), which is the dominant NF-kB
and JNK/p38 activating region of LMP1 and directly in-
teracts with TRADD (TNF receptor-associated death do-
main) (Huen et al., 1995; Izumi and Kieff, 1997b; Kieser et
al., 1997; Eliopoulos and Young, 1998; Eliopoulos et al.,
998, 1999). Recent work demonstrates that the LMP1
epeat region between CTAR1 and CTAR2 interacts with
AK3, thereby activating the STAT pathway in B cells, but
he functional significance of this interaction in epithelial
ells is unknown (Gires et al., 1999). Genetic analysis
as demonstrated that although CTAR2 is the major
ffector domain of LMP1, its activity is not absolutely
ssential for B cell transformation (Kaye et al., 1993, 1995,
999; Izum and Kieff, 1997a).
Although the LMP1 gene is generally well conserved
etween different virus isolates (Miller et al., 1994; Sam-
le et al., 1994), the existence of LMP1 sequence varia-
tion between geographically distinct EBV isolates has
led to speculation that these LMP1 variants might con-
tribute to the development of EBV-associated tumours
(Chen et al., 1992, 1996; Knecht et al., 1995; Cheung et al.,
1998; Sung et al., 1998; Walling et al., 1999). The cloning
and sequencing of the LMP1 gene from EBV isolates
derived from either a Chinese or a Taiwanese NPC have
identified several mutations compared with the prototype
B95.8 strain, including a point mutation leading to loss of
an XhoI restriction site in the first exon, a 30-bp deletion
in the carboxyl-terminus immediately upstream of
CTAR2, and multiple point mutations (Hu et al., 1991;
Chen et al., 1992; Miller et al., 1994; Cheung et al., 1998;
ung et al., 1998). These so-called delLMP1 variants
typified by CAO-LMP1) display increased tumourigenic-
ty in rodent fibroblasts (Li et al., 1996) and the RHEK-1
pithelial cell line (Hu et al., 1991, 1993). Although initial
tudies suggested that EBV isolates carrying delLMP1
re more frequently detected in lymphoproliferative dis-
rders (Knecht et al., 1995; Chen et al., 1996), a more
horough analysis has shown that the incidence of
elLMP1 in EBV-associated tumours reflects the fre-
uency with which this variant is detected in healthy
irus carriers from the same geographical region
Khanim et al., 1996). However, given that delLMP1 is the
redominant form of LMP1 in Chinese populations, it
emains possible that this variant contributes to the de-
elopment of NPC. A recently published functional anal-
sis in lymphoid cells has revealed that CAO-LMP1 is
mpaired in its ability to up-regulate CD40 and CD54
elative to B95.8-LMP1 even though CAO-LMP1 can in-
uce greater activation of NF-kB than B95.8-LMP1 (John-
son et al., 1998). These studies concluded that the 30-bp
deletion was not responsible for these differences and
that sequences outside CTAR2 were involved. Similar
studies using a delLMP1 isolated from a different NPC
(C15) have shown that this LMP1 isolate is also more
efficient at activating NF-kB than B95.8-LMP1 with result-
ant enhanced induction of the EGF receptor in the C33Acarcinoma cell line; these effects of C15-LMP1 were not
due to the 30-bp deletion (Miller et al., 1998b).
Many of the previous studies analysing the functional
differences between distinct LMP1 isolates have used
transient transfection approaches and not examined the
phenotypic consequences of stable LMP1 expression.
Thus we have analysed the effect of stable expression of
B95.8-LMP1 versus CAO-LMP1 on the phenotype of
SCC12F cells, an immortalised but nontumorigenic cell
line derived from stratified squamous epithelium (Daw-
son et al., 1990, 1995, 1998). We now show that although
B95.8-LMP1 is able to induce a range of phenotypic
effects in SCC12F cells, CAO-LMP1 has only limited
effects. The cell signaling basis for this differential be-
haviour is also explored.
RESULTS
Stable expression and cellular localization of B95.8-
LMP1 and CAO-LMP1 in SCC12F cells
Expression of either B95.8-LMP1 or CAO-LMP1 in clones
of SCC12F cells was confirmed by immunoblotting (Fig. 1A).
Clones of SCC12F transfected with B95.8-LMP1 (clones 1, 4,
and 9) show clear expression of the 63-kDa form of LMP1
at levels that are comparable to those observed in the
EBV-transformed LCL, X50–7. Similar levels of expression
were also observed in three CAO-LMP1-expressing clones
(clones, 1, 5, and 6), with the CAO-derived LMP1 protein
migrating at the expected higher molecular weight of 66
kDa due to an increase in the number of internal repeats.
No expression was observed in four vector control clones
(neo-1, 3, 4, and 13). Immunostaining for LMP1 in stable
clones revealed no major differences in their patterns of
subcellular location. Both B95.8-LMP1 (Fig. 1C) and CAO-
LMP1 (Fig. 1D) proteins localised to the plasma membrane
of SCC12F cells and, to a lesser extent, within internal
membranes. Immunostaining of vector control clones gave
only background fluorescence with the CS1–4 monoclonal
antibody mix confirming the specificity of the staining (Fig.
1B).
Both B95.8-LMP1 and CAO-LMP1 induce expression
of the NF-kB regulatable gene A20 and partially
rotect SCC12F from TNF-a-induced cytolysis
LMP1 activation of NF-kB results in the induction of A20,
a protein that plays a role in protecting cells from TNF-a-
induced cytotoxicity (Laherty et al., 1992). To investigate
whether B95.8-LMP1 and CAO-LMP1 induced expression
of this protein to similar degrees, immunoblotting analysis
was performed on cell extracts using a monoclonal anti-
body specific for A20. As shown in Fig. 2A, both B95.8-
LMP1 and CAO-LMP1 induced significant expression of
A20 with all LMP1-positive clones expressing similar
amounts of A20. In contrast, negligible A20 expression was
observed in all four vector control clones. To investigate
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206 DAWSON ET AL.whether LMP1 induction of A20 translated into increased
protection from TNF-a-induced cytolysis, short-term viability
assays were performed. Both B95.8-LMP1- and CAO-
LMP1-expressing clones were significantly more protected
from TNF-a-induced cytolysis compared with vector control
clones (Fig. 2B). Although all LMP1-expressing clones were
similarly resistant at very low concentrations of TNF-a,
significant differences became apparent at concentrations
of .1 ng/ml. At a concentration of 100 ng/ml, both B95.8-
LMP1- and CAO-LMP1-expressing clones were signifi-
cantly more resistant to TNF-a-induced cytolysis than vec-
or control clones.
nlike B95.8-LMP1, CAO-LMP1 does not influence
ell growth
FIG. 1. Stable expression of B95.8-LMP1 and CAO-LMP1 in SCC12F
in stable clones of SCC12F. X50/7, an EBV transformed B cell line, is in
serve as negative controls. LMP1 expression was detected by probin
Immunostaining of stable clones of SCC12F demonstrates the distrib
Teflon-coated microslides were fixed in methanol and immunostained w
clone 4 (C), and CAO-LMP1, clone 1 (D), showed strong staining with t
staining were observed on vector control clones (B).As previously reported (Dawson et al., 1990), the ex-
ression of B95.8-LMP1 in SCC12F cells is associated
d
bith growth inhibition. One striking feature of SCC12F
ells expressing CAO-LMP1 was the apparent lack of
ny growth inhibitory effects. To examine this in more
etail, the growth kinetics of SCC12F cells expressing
95.8-LMP1 or CAO-LMP1 was examined over a 10-day
eriod. The results of a representative experiment are
hown in Fig. 3. Although no obvious differences were
bserved at early time points, clear differences in the
rowth rates of B95.8-LMP1- and CAO-LMP1-expressing
lones were observed at day 6. Compared with SCC12F
ector control and CAO-LMP1 clones, which had
chieved five to seven population doublings by day 6, the
wo B95.8-LMP1 clones (LMP1/1 and LMP1/9) were se-
erely growth-impaired with only marginal increases of
ne or two population doublings over the same period. At
. (A) Immunoblot showing expression of B95.8-LMP1 and CAO-LMP1
as a positive control, whereas three vector control clones of SCC12F
lots with CS1–4, a pool of monoclonal antibodies specific for LMP1.
f B95.8-LMP1 and CAO-LMP1 in situ (B–D). Cells grown for 48 h on
anti-LMP1 monoclonal antibodies CS1–4. Representative B95.8-LMP1,
1-specific monoclonal antibodies, whereas only background levels ofclones
cluded
g the b
ution o
ith theay 10, these effects were even more pronounced, with
oth SCC12F vector control and CAO-LMP1-expressing
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207FUNCTIONAL DIFFERENCES BETWEEN B95.8-LMP1 AND CAO-LMP1clones achieving 10 population doublings compared with
2.5–5 population doublings for the two B95.8-LMP1
clones.
Unlike B95.8-LMP1, CAO-LMP1 fails to induce
expression of cell surface markers and interleukin
production
The induction of CD40 and CD54 (ICAM-1) by LMP1
are useful indicators of its biological activity (Wang et al.,
988, 1990; Dawson et al., 1990; Rowe et al., 1994; Huen
t al., 1995; Johnson et al., 1998). As a previous study had
FIG. 2. Both B95.8-LMP1 and CAO-LMP1 induce A20 induction in
SCC12F cells and protect these cells from TNF-a-induced cytotoxicity.
A) Immunoblot showing expression of A20 in SCC12F clones stably
xpressing B95.8-LMP1 or CAO-LMP1. X50/7, an EBV transformed B
ell line, is included as a positive control, whereas three vector control
lones of SCC12F serve as negative controls. A20 expression was
etected by probing with a monoclonal antibody specific for the A20.
B) The effect of B95.8-LMP1 and CAO-LMP1 on TNF-a induced cyto-
toxicity was assessed in MTT assays in response to increasing con-
centrations of TNF-a. Data are shown relative to that of cells treated
with 10 mg/ml cycloheximide alone and are representative of three
imilar experiments.hown that CAO-LMP1 was defective in its ability to
nduce cell surface CD40 and CD54 expression in lym-
a
choid cells (Johnson et al., 1998), we were interested in
nvestigating whether the same phenomenon was ob-
erved in epithelial cells stably expressing CAO-LMP1.
he cell surface profiles of SCC12F cells expressing
95.8-LMP1 and CAO-LMP1 were investigated by flow
ytometry using monoclonal antibodies specific for
D40, CD54, and CD44. A monoclonal antibody specific
or CD23 served as a negative control in these studies.
he results from a representative analysis are shown in
ig. 4A. Expression of the lymphoid specific marker
D23 gave only low levels of background staining on
oth vector control and LMP1-expressing clones [mean
luorescence intensity (MFI) values of 10–15]. In contrast,
he expression of CD40, CD54, and CD44 was clearly
p-regulated on cells expressing B95.8-LMP1. Although
he magnitude of the induction was variable for each
arker, the expression of CD40 was almost twice as
igh on B95.8-LMP1-expressing clones compared with
ector control clones (MFI of 30–40 versus 18–19). The
evels of CD54 expression were more variable but were
ignificantly higher than vector control clones (MFI val-
es of 80–150 versus 50–60), whereas the expression of
D44 was clearly higher on all three B95.8-LMP1 clones
xamined (MFI values of 95–110 versus 40–65). In
arked contrast, all three CAO-LMP1 clones expressed
evels of CD40, CD54, and CD44 that were equivalent to
hose observed on vector control clones.
An additional phenotypic consequence of LMP1 ex-
ression is induction of the secretion of IL-6 (Eliopoulos
t al., 1997, 1999) and IL-8 (Eliopoulos et al., 1999). To
valuate the effects of B95.8-LMP1 and CAO-LMP1 on
he levels of IL-6 and IL-8 secretion from SCC12F cells,
upernatants were collected from subconfluent SCC12F
ultures seeded at the same cell density and the levels
f IL-6 and IL-8 secreted into the growth medium were
etermined by ELISA. As demonstrated in Fig. 4B, B95.8-
MP1-expressing SCC12F clones secreted far greater
uantities of both IL-6 and IL-8 than vector control
lones, whereas the levels of IL-6 and IL-8 secretion from
he two CAO-LMP1 expressing clones were only margin-
lly greater than those of the controls.
95.8-LMP1 but not CAO-LMP1 induces alterations in
ell morphology and blocks terminal differentiation
Our previous work has demonstrated that expression
f B95.8-LMP1 induced a marked alteration in the mor-
hology of SCC12F cells in monolayer culture (Dawson
t al., 1990). This is confirmed in the present study as
table clones expressing B95.8-LMP1 displayed poorer
ntercellular contact and failed to stratify to the same
xtent as representative vector control clones (data not
hown). This was in marked contrast to clones express-
ng CAO-LMP1, which maintained a cuboidal morphology
nd were almost indistinguishable from vector control
lones (data not shown). In organotypic raft culture, vec-
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208 DAWSON ET AL.tor control SCC12F clones routinely gave rise to simple
differentiating epithelial structures that generated a
clearly defined basal cell layer and two or three layers of
flatter differentiating cells as demonstrated by immuno-
staining with the AE1 pan-keratin monoclonal antibody
(Fig. 5A). In agreement with our previous findings, B95.8-
LMP1-expressing clones produced much thicker and
less well-organised epithelial structures that were rou-
tinely three or four times the thickness of vector control
rafts (Fig. 5C). However, unlike B95.8-LMP1, CAO-LMP1-
expressing clones gave rise to raft structures that were
identical to those formed by SCC12F vector control cells
and retained their capacity for terminal differentiation
(Fig. 5E). Thus, although the differentiation-associated
antigen involucrin was clearly not expressed in supra-
basal cell layers of B95.8-LMP1-expressing rafts (Fig.
5D), expression of this protein was clearly evident in
differentiating suprabasal cell layers of both the SCC12F
vector control (Fig. 5B) and CAO-LMP1 raft structures
(Fig. 5F). Similar results were obtained in at least three
separate raft experiments with representative B95.8-
LMP1- and CAO-LMP1-expressing clones.
FIG. 3. CAO-LMP1 does not induce the growth-inhibitory effects ass
representative SCC12F vector control, B95.8-LMP1-expressing, and CA
was determined at 48-h intervals by trypan blue exclusion to estim
representative of two experiments.
FIG. 4. Unlike B95.8-LMP1, CAO-LMP1 fails to induce cell surface a
AO-LMP1 to induce cell surface antigen expression in SCC12F cells w
og scale. Monoclonal antibodies used include antibodies to CD23, CD
he secretion of IL-6 (i) and IL-8 (ii) was determined by ELISA. Conditio
AO-LMP1-expressing clones was analysed. The results are presented a
epresentative of two experiments.Both B95.8-LMP1 and CAO-LMP1 induce NF-kB, but
AO-LMP1 weakly activates AP-1
One possible explanation for the inability of CAO-
MP1 to induce the various phenotypic effects observed
ith B95.8-LMP1 in SCC12F cells is differences in the
elative activation of signaling pathways such as the
F-kB and JNK/AP-1. To address this possibility, we used
electrophoretic mobility shift assays (EMSAs) to examine
the constitutive levels of NF-kB and AP-1 activity in the
table SCC12F clones expressing either B95.8-LMP1 or
AO-LMP1. NF-kB complexes were detected using a
probe containing concensus kB binding sites from the
HIV LTR, and AP-1 complexes were detected using a
probe containing concensus AP-1 binding sites from the
collagenase promoter (Gires et al., 1999). Significant
NF-kB activity was observed in nuclear extracts derived
from B95.8-LMP1- and CAO-LMP1-expressing clones, al-
though somewhat lower NF-kB activity was observed in
AO-LMP1 clones 5 and 6 compared with the other
MP1-positive clones (Fig. 6A). Although significant AP-1
ctivity was observed in SCC12F clones expressing
with B95.8-LMP1 expression in SCC12F cells. The growth kinetics of
1-expressing clones was analysed over a 10-day period. Cell number
ble cell number. Data are the means of triplicate counts and are
expression and cytokine secretion. (A) The ability of B95.8-LMP1 and
termined by FACS analysis. Data are presented as MFI on an arbitrary
44, and CD54. (B) The ability of B95.8-LMP1 and CAO-LMP1 to induce
dium from representative vector control, B95.8-LMP1-expressing, andociated
O-LMPntigen
as de
40, CD
ned mes the mean of duplicate determinations (shown in pg/ml) and are
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210 DAWSON ET AL.B95.8-LMP1, much weaker activity was found in CAO-
LMP1-expressing cells (Fig. 6B); however, AP-1 activity in
the CAO-LMP1 clones was still greater than that ob-
served in the vector control clones. To investigate
whether B95.8-LMP1 and CAO-LMP1 activated qualita-
tively different species of NF-kB, supershift experiments
were performed with antibodies specific for p50, p65,
and c-rel subunits. As can be seen in Fig. 6C, both B95.8-
and CAO-LMP1 activated NF-kB complexes that were
omposed of both p50 homodimers and p50/p65 het-
FIG. 5. Expression of B95.8-LMP1 but not CAO-LMP1 is associated
with alterations in the differentiation capacity of SCC12F cells in orga-
notypic rafts. Immunostaining of sections of control clone neo-1 (A and
B), B95.8-LMP1 clone 9 (C and D), and CAO-LMP1 clone 1 (E and F)
using monoclonal antibody AE1 (Woodcock-Mitchell et al., 1982)
against type 1 keratins (A, C, and E) and a polyclonal rabbit antiserum
against involucrin (Biogenesis) (B, D, and F). Magnification, 2503.rodimers. The apparent inability of CAO-LMP1 to induce
robust AP-1 activation prompted us to examine
t
ohether this was due to an inability of CAO-LMP1 to
ctivate c-jun N-terminal kinase activity to the same
xtent as B95.8-LMP1. In vitro kinase assays were per-
ormed on extracts derived from SCC12F vector control,
95.8-LMP1-expressing, and CAO-LMP1-expressing
lones, and the ability of endogenous JNK to phosphor-
late GST-jun substrate was examined. Interestingly, all
MP1-expressing clones were found to have elevated
NK activity at levels that were clearly higher than those
bserved with vector control clones (Fig. 6D). The degree
f JNK activation was similar between B95.8-LMP1 and
AO-LMP1 clones (Fig. 6D).
DISCUSSION
In this study, we have demonstrated that the CAO-
MP1 isolate fails to induce many of the morphological
nd phenotypic changes associated with B95.8-LMP1
xpression in a human epithelial cell background. This is
erhaps surprising given previous work suggesting that
AO-LMP1 is more oncogenic than B95.8-LMP1 in both
odent fibroblasts and in the RHEK-1 epithelial cell line
Hu et al., 1993). However, other studies with RHEK-1
ells failed to identify significant differences between
95.8-LMP1 and CAO-LMP1 with regard to induction of
roliferation and blockade of differentiation (Zheng et al.,
994). It is nevertheless clear that RHEK-1 cells respond
ery differently than SCC12F cells with regard to the
ffects of LMP1 expression, and this may reflect the
istinct nature of the epithelial cell environment in the
wo cell lines. RHEK-1 cells were generated by immor-
alisation with an adenovirus 12–SV40 hybrid virus and
re exceptionally susceptible to transformation by a va-
iety of agents, including oncogenes, chemical carcino-
ens, and ionizing radiation (Yang et al., 1992; Allen-
offmann et al., 1993; Lee et al., 1993; Razzzaque et al.,
993). SCC12F cells are a subclone derived from a squa-
ous cell carcinoma, and they behave like primary ker-
tinocytes in vitro and are relatively resistant to transfor-
ation (Rheinwold et al., 1981; Parkinson et al., 1983).
ur previous work suggests that SCC12F cells are ideal
or studying the effects of stably expressed transfected
enes on the epithelial cell phenotype, particularly with
egard to terminal differentiation (Dawson et al., 1990,
995, 1998). Thus it is surprising that despite equivalent
evels of stable expression, CAO-LMP1 is unable to in-
uce most of the phenotypic effects observed with B95.8-
MP1 in the same cell background. These data, how-
ver, are consistent with recent work using transient
ransfection in human B and T cell lines that demon-
trates that although CAO-LMP1 is able to induce robust
ctivation of NF-kB, it is relatively impaired in its ability to
nduce various phenotypic effects such as up-regulation
f CD40 and CD54 (Johnson et al., 1998). Our data extendhis observation by demonstrating that CAO-LMP1 not
nly is unable to induce expression of CD40 and CD54
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predominant complex, indicated by an arrow, contains p65/p50 het-
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211FUNCTIONAL DIFFERENCES BETWEEN B95.8-LMP1 AND CAO-LMP1but also fails to stimulate secretion of IL-6 and IL-8, to
inhibit cell growth, and to block epithelial cell differenti-
ation. The inability of CAO-LMP1 to induce phenotypic
effects does not appear to be due to defective activation
of NF-kB as the B95.8-LMP1 and CAO-LMP1 transfec-
tants displayed comparable levels of activity and the
NF-kB species present in the activated complexes ap-
pear to be identical on supershift analysis. In support of
this observation is the finding that both LMP1 proteins
were able to induce similar levels of A20, a protein
known to be under the dominant control of NF-kB (La-
erty et al., 1992; Miller et al., 1997), and that this A20
xpression correlated with relative protection from TNF-
a-induced cytotoxicity. However, CAO-LMP1 was unable
to induce expression of other genes that also contain
NF-kB sites in their promoters, such as CD40, CD54, IL-6,
and IL-8 (Grimaldi et al., 1991; Voraberger et al., 1991).
This emphasises the complexity of transcriptional regu-
lation and highlights the involvement of multiple signals
in controlling promoter function.
The inability of CAO-LMP1 to induce many of the
phenotypic effects associated with B95.8-LMP1 expres-
sion despite activating similar levels of NF-kB suggests
that CAO-LMP1 is defective in engaging other LMP1-
activated signaling pathways. Recent work demonstrates
that LMP1 can stimulate both the JNK and p38 MAP
kinase pathways (Kieser et al., 1997; Eliopoulos and
Young, 1998; Eliopoulos et al., 1999) and that these con-
tribute to the transcriptional activity of certain genes
such as IL-6 and IL-8. It is therefore interesting that
CAO-LMP1 appears to be less efficient at inducing AP-1
activity than B95.8-LMP1, and this might explain the fail-
ure of CAO-LMP1 to induce up-regulation of cell surface
markers and cytokine secretion, as these genes may be
coregulated by NF-kB and AP-1. As JNK activation by
MP1 is mediated via CTAR-2 and requires direct inter-
ction with TRADD (Izumi and Kieff 1997a; Eliopoulos et
l., 1998), it is possible that the CTAR-2 region of CAO-
MP1 is less efficient at engaging JNK due to a weaker
nteraction with TRADD. However, the amino acid se-
uence over this region is well conserved between B95.8
nd CAO, and consistent with this, we found that JNK
ctivation by CAO-LMP1 is similar to that induced by
95.8-LMP1. Thus the weaker AP-1 activity induced by
AO-LMP1 may be due to additional factors that impinge
erodimers. (B) The same nuclear extracts were then subjected to EMSA
to detect the basal levels of AP-1 activity using a 32P-labeled collage-
ase TRE oligonucleotide as a probe. (C) Supershift experiment with
ntibodies to p50, p65, and c-rel demonstrating that B95.8-LMP1 and
AO-LMP1 activate NF-kB transcription factor complexes that are
composed of both p50 and p65 subunits. Arrows denote supershifted
complexes containing either p50 or p65. (D) In vitro kinase assay
showing that both B95.8-LMP1 and CAO-LMP1 are able to activateFIG. 6. Both B95.8-LMP1 and CAO-LMP1 activate NF-kB and AP-1
ranscription factors. Nuclear extracts isolated from SCC12F cells ex-
ressing B95.8-LMP1 or CAO-LMP1 were subjected to EMSA to detect
he basal levels of NF-kB (A) and AP-1 activity (B). (A) A 32P-labeled
c-Jun N-terminal kinase activity to similar extents. Arrow indicates the
phosphorylated substrate, GST-c-jun.
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212 DAWSON ET AL.on the efficient activation of AP-1, such as the influence
of other signaling pathways. In this regard, recent work
indicates that both the p38 and ERK MAP kinases can
affect AP-1 activation in keratinocytes by regulating c-fos
xpression (Chen and Bowden, 1999), and thus the abil-
ty of CAO-LMP1 to activate these pathways when stably
xpressed in epithelial cells is worthy of examination.
ur preliminary data indicate that both types of LMP1
ctivate the p38 kinase to the same extent in the stable
CC12F transfectants. Because many of the amino acid
ifferences between CAO-LMP1 and B95.8-LMP1 lie
ithin the N-terminus and transmembrane loops, these
egions of the protein could have a direct effect on cell
ignaling or influence the activity of CTAR1 and CTAR2 by
ffecting the conformation of the LMP1 cytoplasmic tail.
he recent demonstration of a cooperative effect be-
ween CTAR1 and CTAR2 on the up-regulation of CD54
ay be of relevance because it suggests that a physical
nteraction between these domains is necessary for ef-
icient LMP1 signaling (Floettmann et al., 1998). This
ooperation between CTAR1 and CTAR2 may be defec-
ive in CAO-LMP1, and further experiments addressing
his using chimeric combinations of CAO-LMP1 and
95.8-LMP1 are under way. Alternatively, it is possible
hat additional yet-to-be-identified signaling pathways
re differentially activated by B95.8-LMP1 versus CAO-
MP1. The recent demonstration that LMP1 activates
embers of the STAT family of transcription factors
hrough the binding and activation of JAK proteins is a
elevant case in point (Gires et al., 1999). Interestingly,
AK3 binding does not map to the known C-terminal
ctivating regions CTAR1 or CTAR2 but maps to proline-
ich domains within the repeat regions. Although JAK3 is
ot expressed in epithelial cells, these observations
emonstrate that LMP1 is able to engage additional
ignaling molecules through regions of its cytoplasmic
-terminus that are distinct from those that engage
F-kB and JNK/p38. However, the possibility that differ-
ential activation of other members of the JAK/STAT path-
way or of other yet-to-be-identified LMP1-activated sig-
nals accounts for the biological differences between
B95.8-LMP1 and CAO-LMP1 cannot be excluded and is
worthy of further investigation.
The ability of B95.8-LMP1 to block the terminal differ-
entiation of human stratified squamous epithelial cells is
confirmed in this study. Although the relative contribution
of different signaling pathways to this effect remains
unknown, both AP-1 and NF-kB have been implicated in
the regulation of epithelial differentiation. Within strati-
fied squamous epithelium, differentiation-dependent ex-
pression of AP-1 family members has been observed,
suggesting a role for these proteins in the temporal and
spatial regulation of gene expression during epithelial
differentiation (Welter and Eckert, 1995). The precise rel-
evance of these observations in terms of the possible
role of different AP-1 family members in controlling thecommitment of epithelial cells to the differentiation pro-
cess remains unknown. By contrast, increasing evidence
implicates the NF-kB family as key regulators of epithe-
ial cell growth and differentiation. In normal epidermis,
F-kB is activated as cells migrate from the basal layer,
suggesting a role for NF-kB in epithelial cell differentia-
ion (Seitz et al., 1998). Functional inhibition of NF-kB by
expression of dominant negative NF-kB inhibitory pro-
eins (IkBs) has been shown to block differentiation and
romote epithelial hyperplasia (Seitz et al., 1998). More
ecent studies on the function of the IkB kinase, a large
ultiprotein complex consisting of IkB kinase kinase
IKK) subunits, support a role for NF-kB in the terminal
ifferentiation of epithelial cells. Thus IKKa (IkB kinase
kinase a) null mice are born with limb and skeletal
abnormalities and develop a hyperplastic epidermis
characterised by increased cell proliferation and se-
verely diminished differentiation (Hu et al., 1999; Takeda
t al., 1999). This implicates IKKa-mediated NF-kB acti-
vation in the regulation of normal epithelial cell differen-
tiation. Interestingly, cells from IKKa null mice are still
able to activate NF-kB in response to TNF-a and IL-1 as
this appears to be predominantly regulated by IKKb (Li et
l., 1999). Thus it appears that IKKa plays a fundamental
role in regulating cell fate (developmental patterning)
and epithelial cell differentiation and is activated by mor-
phogenic signals. The degree to which NF-kB activation
through IKKa or IKKb influences the subsequent tran-
criptional regulation of different downstream genes re-
ains unknown. A recent study demonstrated that both
KKa and IKKb are required for LMP1-induced NF-kB
activation from CTAR1 and CTAR2 (Sylla et al., 1998); a
more profound inhibitory effect of dominant negative
IKKa was observed. Reconciling these data with the
bility of B95.8-LMP1 to block epithelial differentiation is
ore complex. It could be that the constitutive activation
f NF-kB by B95.8-LMP1 blocks the morphogenic signals
esponsible for IKKa-induced NF-kB activation while pro-
moting the IKKb pathway. This would result in the inhi-
bition of epithelial differentiation but the stimulation of
the NF-kB responsive genes involved in cytokine-medi-
ted responses such as CD54 and the interleukins. The
bility of the IkB kinase complex to transmit and regulate
different signals through differential activation of the IKKs
has been demonstrated and may further explain the
effects of LMP1 (May and Gosh, 1999). Extending this
argument to account for the inability of CAO-LMP1 to
block epithelial differentiation while still retaining the
ability to activate NF-kB is more difficult. Apart from the
ossible role of other signaling pathways as discussed
arlier, defects in both the differential activation of the
KKs and the downstream pathways responsible for reg-
lating NF-kB responsive gene transcription may ac-
count for the severely impaired activity of CAO-LMP1.
Such differential effects may account for the ability of
CAO-LMP1 to induce expression of the NF-kB-regulated
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213FUNCTIONAL DIFFERENCES BETWEEN B95.8-LMP1 AND CAO-LMP1A20 gene but not of other NF-kB-regulatable genes.
urther studies examining the relative contribution of
KKa and IKKb to NF-kB activation induced by B95.8-
MP1 and CAO-LMP1 are clearly warranted, and mu-
ants of B95.8-LMP1 should help to map the signaling
athways responsible for the inhibition of epithelial dif-
erentiation.
Overall, this study has identified functional differences
etween the prototype B95.8-LMP1 and the NPC-derived
AO-LMP1 isolate when stably expressed in human ep-
thelial cells. Our findings, along with those of others,
learly demonstrate that sequence differences between
rototype and variant delLMP1 genes translate into func-
ional differences in vivo. With regard to CAO-LMP1, re-
ent work indicates that sequences outside the CTAR2
omain are responsible for the distinct effects of tran-
iently expressed CAO-LMP1 in lymphoid cells (Johnson
t al., 1998), and these may also be responsible for the
unctional differences observed in this study. To address
his issue, studies are currently under way to determine
he effects of B95.8-LMP1 mutants and of chimerae of
AO- and B95.8-LMP1 on the epithelial cell phenotype.
hether the CAO-LMP1 isolate is representative of other
elLMP1 variants or whether it is unique among variants
arrying the 30-bp deletion requires further assessment.
hus it is important to isolate and sequence other LMP1
enes from NPC biopsies and study their behaviour in
itro to help determine the role of variant LMP1 genes in
he pathogenesis of NPC. Although the predominantly
nert phenotypic behaviour of CAO-LMP1 when stably
xpressed in human epithelial cells is puzzling, contin-
ed study of this and other variant LMP1 isolates should
elp to further dissect the signaling pathways activated
y LMP1 as well as provide insights into the contribution
f LMP1 sequence variation to the pathogenesis of EBV-
ssociated tumours.
MATERIALS AND METHODS
ell culture and isolation of SCC12F cells stably
xpressing B95.8- and CAO-LMP1
The SCC12F cell line was grown in DMEM/F-12 (3:1
ixture) supplemented with 5% foetal calf serum (GIBCO,
aisley, Scotland), 2 mM glutamine, hydrocortisone (0.4
mg/ml) (Up-John Ltd., UK), and the antibiotics penicillin
(1000 U/ml) and streptomycin (1 mg/ml) (Sigma Chemi-
cal, Poole, Dorset, UK). For routine culture, SCC12F cells
were grown at clonal density (105 cells/9-cm petri dish)
on an irradiated 3T3 fibroblast feeder cell layer (Parkin-
son et al., 1983). Stable clones of the SCC12F cell line
xpressing either B95.8 or CAO-LMP1 were generated
y electroporation with either pCM1B95.8 or pCM1CAO,
espectively. The empty vector pCM1 was also included
s a negative control. Stable, drug-resistant clones weresolated after seeding at clonal density on a G418-resis-
ant 3T3 feeder cell layer and selection in medium con-
f
(taining 400 mg/ml G418 (GIBCO). Single G418-resistant
lones were cloned and subsequently expanded for fur-
her analysis.
nalysis of B95.8- and CAO-LMP1 expression in
table SCC12F cells
LMP1 expression was confirmed using standard im-
unoblotting procedures. Briefly, 100 mg of a total pro-
tein extract from each clone (equivalent to ;106 cells)
was separated on a 7.5% SDS-polyacrylamide gel. Sep-
arated proteins were electroblotted onto nitrocellulose
membranes and, after blocking for 2 h with PBS-Tween
(0.1%) containing 5% fat-free skimmed milk, incubated
overnight with CS1–4, a pool of murine monoclonal an-
tibodies specific for the cytosolic C-terminus of LMP1
(Rowe et al., 1987). After two 60-min washes in PBS-
Tween (0.1%), the nitrocellulose membrane was incu-
bated for 90 min with horseradish peroxidase-conju-
gated goat anti-mouse immunoglobulin (1:1000) (Sigma).
After an additional two 60-min washes in PBS-Tween
(0.1%), antibody–protein complexes were visualised by
enhanced chemiluminescence (ECL; Amersham Interna-
tional, Buckinghamshire, UK).
Analysis of cell growth kinetics
Exponentially growing cultures of SCC12F vector con-
trol, B95.8-LMP1-expressing, and CAO-LMP1-expressing
clones were recovered as single-cell suspensions by
trypsinisation. Cells were plated out at a concentration of
104 cells/well in a 6-well plate in duplicate (Nunc).
Twenty-four hours after seeding, the medium was re-
laced to removed nonadherent cells; thereafter, cells
ere cultured for a period of 10 days with a medium
hange at days 3 and 6. Cell growth was assessed at
8-h intervals, and viable cell number was determined by
rypan blue exclusion. Cell number is expressed as cells
104/ml.
ensitivity of SCC12F cells expressing B95.8-LMP1
nd CAO-LMP1 to TNF-a
Cultures of vector control, B95.8-LMP1-expressing,
and CAO-LMP1-expressing clones were trypsinised and
plated out at 104 cells/well onto a 96-well plate in tripli-
ate. The next day, cells were treated with various con-
entrations of TNF-a (0.1–100 ng/ml) (R and D Systems
Europe, Oxford, UK) in the presence of 10 mg/ml cyclo-
eximide (Sigma). At 24–48 h after treatment, cell viability
as assessed using the MTT (3-[4,4-dimethylthiazol-2-
l]-2,5-diphenyl tetrazolium bromide; Sigma) assay
Mossmann, 1983). Briefly, 20 ml of a 5 mg/ml stock of
TT in PBS was added to each well, and the cells were
ncubated with the substrate for 5 h. After the incubation,
pent medium was aspirated from the wells, and theormazan crystals solubilised in 200 ml of DMSO
Fisons). The absorbance was then determined at 550
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214 DAWSON ET AL.nm on a Becton Dickinson (Le Pont de Claix, France)
Multiscan. In each case, viability is expressed as a
percentage relative to cells treated with cycloheximide
(10 mg/ml) alone.
low cytometric analysis for cell surface antigen
xpression
Subconfluent cultures of vector control, B95.8-LMP1-
xpressing, and CAO-LMP1-expressing clones were re-
overed by mild trypsination (0.0125% trypsin–0.02%
DTA). Single-cell suspensions were collected by cen-
rifugation, counted, and distributed into the wells of a
icrotitre plate at 2.5 3 105 cells/well. Then, 50 ml of
prediluted antibody was added to each well, and the
plate was incubated on ice for 45 min. Cell surface
markers examined in this study included monoclonal
antibodies specific for CD23 (DAKO, Bucks, UK), CD40
(G28.5; a gift from E. Clark), CD44H (Novocastra, New-
castle, UK), and CD54 (Serotec, Oxford, UK). After three
washes in cold PBS (4°C), the cells were resuspended in
50 ml of FITC-labeled goat anti-mouse antibodies
Sigma) and incubated on ice for an additional 45 min.
fter an additional three washes in precooled PBS (4°C),
he cell suspensions were fixed in 1% paraformaldehyde
nd processed for FACS analysis. Fluorescent staining of
ell surface markers was analysed by flow cytometry
ith a Coulter EPICS XL FACSCAN. Values are presented
s MFI values on an arbitrary log scale.
nalysis of cytokine secretion
Cultures of actively growing vector control, B95.8-
MP1-expressing, and CAO-LMP1-expressing clones
ere trypsinised and plated out at 5 3 105 cells/5-cm
late. The next day, growth medium was aspirated and
eplaced with growth medium supplemented with 1%
erum. 48 hrs later, the medium was collected for anal-
sis. Cell debris was removed by centrifugation, and
onditioned medium was frozen as aliquots at 270°C
efore analysis. The amount of IL-6 and IL-8 present in
he conditioned medium was determined by ELISA using
ommercially available kits from Pelikine (Amsterdam).
ytokine levels are expressed as pg/ml.
ollagen raft culture and immunostaining
Vector control, B95.8-LMP1-expressing, and CAO-
MP1-expressing clones were analysed for their ability
o terminally differentiate in the collagen raft system as
reviously described (Dawson et al., 1990, 1995, 1998).
riefly, 2 3 105 epithelial cells were seeded onto a
ollagen lattice (Collaborative Research, UK) containing
T3 fibroblast feeder cells (105 cells/ml) and grown until
confluent. Thereafter, the lattice was carefully transferred
to a stainless steel grid, and the epithelial culture was
exposed at the air/liquid interface for an additional 3
weeks. Under such conditions, SCC12F cells stratify andterminally differentiate. After the appropriate time, indi-
vidual rafts were snap-frozen in liquid nitrogen. Frozen
sections (6 mm) were cut from representative rafts, fixed
in cold acetone and stored at -70°C prior to use. Analysis
of terminal differentiation was performed using a mono-
clonal antibody specific for acidic keratin family mem-
bers, AE1 (ICN), and a polyclonal antisera to involucrin
(Biogenesis). Bound antibody was visualised using the
appropriate FITC conjugated secondary antibodies
(Sigma). Raft sections were examined using an Olympus
UV-fluorescence microscope.
Analysis of NF-kB and AP-1 binding activity by EMSA
Cultures of vector control, B95.8-LMP1-expressing,
nd CAO-LMP1-expressing clones were trypsinised and
lated out at 2 3 106 cells/9-cm plate. The next day, cell
nuclei were isolated by resuspending cells in a solution
containing 10 mM HEPES (pH 7.9), 1.5 mM magnesium
chloride, 10 mM potassium chloride, and 0.5 mM DTT,
and protease inhibitors and were subjected to lysis in a
buffer of 20 mM HEPES (pH 7.9), 25% glycerol, 1.5 mM
magnesium chloride, 0.42 M sodium chloride, 0.2 mM
EDTA, 0.5 mM DTT, and protease inhibitors. Protein con-
centration of isolated nuclear extracts was determined
by the Bio-Rad protein assay according to manufacturer’s
instructions (Bio-Rad, Hercules, CA). For EMSAs, a 29-bp
HIV-kB probe (59-GATCAGGGACTT-TCCGCTGGGGAC-
TTCC-39) or a 22-bp collagenase TRE probe (59-AGCT-
GATGAGTC-AGCCGGATC-39) were made by annealing
omplementary synthetic oligonucleotides and end-la-
eling using [g-32P]ATP (Amersham) and T4 polynucle-
otide kinase (Boehringer-Mannheim). Binding reactions
containing 10 mg of nuclear protein extract, 1 mg of
oly(dI/dC) (Pharmacia), 0.1 ng of HIV-kB or TRE probe
abeled to a specific activity of 2 3 108 cpm/mg, and
binding buffer (4% glycerol, 1 mM EDTA, 5 mM DTT, 0.01
M Tris–HCl, pH 7.5, and 5 mM KCl) in a volume of 20 ml
ere incubated for 30 min at room temperature and then
esolved by electrophoresis through a 5% polyacryl-
mide gel in a 0.553 TBE buffer. Gels were then dried
own and exposed to X-ray film for autoradography
Kodak). For supershift experiments, nuclear extracts
ere incubated with 1 ml of polyclonal antisera to the
ubunit of interest for 30 min on ice before electrophore-
is. Polyclonal antisera to p65, p50, and c-rel were pur-
hased from Santa Cruz.
nalysis of Jun-N-terminal kinase activity by in vitro
inase assay
JNK assays were performed as previously described
Eliopoulos and Young, 1998). Briefly, 80–90% confluent
ultures of SCC12F vector control, B95.8-LMP1-express-
ng, or CAO-LMP1-expressing clones were lysed in 500
ml of kinase lysis buffer (20 mM Tris, pH 7.6, 0.5% Triton
X-100, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 2 mM
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215FUNCTIONAL DIFFERENCES BETWEEN B95.8-LMP1 AND CAO-LMP1sodium orthovanadate, 10 mg/ml aprotinin, 10 mg/ml leu-
eptin, and 1 mM DTT) on ice for 15 min. Nonsolubilised
aterial was pelleted by centrifugation, and the protein
oncentration was determined by Lowry assay using a
ommercially available assay (Bio-Rad). c-Jun N-terminal
inases were immunoprecipitated from 250 mg of total
protein extracts using 1 mg of JNK1 (C17; Santa Cruz) by
incubating end-over-end at 4°C for 1 h. Protein–antibody
complexes were collected using Protein G–Sepharose
(Pharmacia) for 2–3 h. After immunoprecipitation, the
beads were washed once with kinase lysis buffer and
twice with kinase assay buffer (20 mM HEPES, pH 7.5, 20
mM b-glycerophosphate, 10 mM MgCl, 1 mM DTT, 50
mM sodium vanadate, and 1 mg/ml leupeptin). After the
ast wash, the beads were drained with a fine needle and
esuspended in 40 ml of kinase assay buffer containing 2
mg of GST-jun substrate (Stratagene, La Jolla, CA), 20 mM
old ATP, and 3 mCi of [g-32P]ATP. Kinase reactions were
arried out at 30°C for 30 min and stopped by the
ddition of 40 ml of 63 Laemmli’s buffer and boiling for 5
min. Samples were then analysed on a 10% SDS–poly-
acrylamide gel. After staining with Coomassie blue to
confirm that equal amounts of substrate were used, the
gel was dried and exposed to X-ray film (Kodak). The
degree of JNK kinase activation was then determined by
densitometric scanning of the X-ray film and phospho-
rimaging.
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